Literature DB >> 36255617

Development of a Cellular Model Mimicking Specific HDAC Inhibitors.

Lena Hess1, Verena Moos1, Christian Seiser2.   

Abstract

Class I histone deacetylases (HDACs) are important regulators of cellular functions in health and disease. HDAC1, HDAC2, HDAC3, and HDAC8 are promising targets for the treatment of cancer, neurological, and immunological disorders. These enzymes have both catalytic and non-catalytic functions in the regulation of gene expression. We here describe the generation of a genetic toolbox by the CRISPR/Cas9 methodology in nearly haploid human tumor cells. This novel model system allows to discriminate between catalytic and structural functions of class I HDAC enzymes and to mimic the treatment with specific HDAC inhibitors.
© 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  CRISPR/Cas9; HDAC inactivation; HDAC inhibition; Knock-in; Knockout; Transgenic cells

Mesh:

Substances:

Year:  2023        PMID: 36255617     DOI: 10.1007/978-1-0716-2788-4_4

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  39 in total

Review 1.  Multiple roles of class I HDACs in proliferation, differentiation, and development.

Authors:  Nina Reichert; Mohamed-Amin Choukrallah; Patrick Matthias
Journal:  Cell Mol Life Sci       Date:  2012-07       Impact factor: 9.261

Review 2.  Recent advances in class IIa histone deacetylases research.

Authors:  Yodita Asfaha; Christian Schrenk; Leandro A Alves Avelar; Alexandra Hamacher; Marc Pflieger; Matthias U Kassack; Thomas Kurz
Journal:  Bioorg Med Chem       Date:  2019-09-06       Impact factor: 3.641

Review 3.  Targeting Class I Histone Deacetylases in a "Complex" Environment.

Authors:  Christopher J Millard; Peter J Watson; Louise Fairall; John W R Schwabe
Journal:  Trends Pharmacol Sci       Date:  2017-01-28       Impact factor: 14.819

Review 4.  HDAC family: What are the cancer relevant targets?

Authors:  Olaf Witt; Hedwig E Deubzer; Till Milde; Ina Oehme
Journal:  Cancer Lett       Date:  2008-09-27       Impact factor: 8.679

5.  HDAC8 Catalyzes the Hydrolysis of Long Chain Fatty Acyl Lysine.

Authors:  Pornpun Aramsangtienchai; Nicole A Spiegelman; Bin He; Seth P Miller; Lunzhi Dai; Yingming Zhao; Hening Lin
Journal:  ACS Chem Biol       Date:  2016-08-05       Impact factor: 5.100

6.  Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor.

Authors:  Alessandro Vannini; Cinzia Volpari; Gessica Filocamo; Elena Caroli Casavola; Mirko Brunetti; Debora Renzoni; Prasun Chakravarty; Chantal Paolini; Raffaele De Francesco; Paola Gallinari; Christian Steinkühler; Stefania Di Marco
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-11       Impact factor: 11.205

Review 7.  Lysine acetylation: codified crosstalk with other posttranslational modifications.

Authors:  Xiang-Jiao Yang; Edward Seto
Journal:  Mol Cell       Date:  2008-08-22       Impact factor: 17.970

Review 8.  Strategies To Design Selective Histone Deacetylase Inhibitors.

Authors:  Jelena Melesina; Conrad V Simoben; Lucas Praetorius; Emre F Bülbül; Dina Robaa; Wolfgang Sippl
Journal:  ChemMedChem       Date:  2021-02-19       Impact factor: 3.466

Review 9.  Transcription and beyond: the role of mammalian class I lysine deacetylases.

Authors:  Mirjam Andrea Moser; Astrid Hagelkruys; Christian Seiser
Journal:  Chromosoma       Date:  2013-10-30       Impact factor: 4.316

Review 10.  Histone Deacetylases Inhibitors in Neurodegenerative Diseases, Neuroprotection and Neuronal Differentiation.

Authors:  Surabhi Shukla; Babu L Tekwani
Journal:  Front Pharmacol       Date:  2020-04-24       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.